| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303146 | BRISTOL MYERS SQUIBB | Solid oral dosage form comprising a combination of metformin and glibenclamide |
Jul, 2019
(4 years ago) | |
|
US6303146 (Pediatric) | BRISTOL MYERS SQUIBB | Solid oral dosage form comprising a combination of metformin and glibenclamide |
Jan, 2020
(4 years ago) | |
Glucovance is owned by Bristol Myers Squibb.
Glucovance contains Glyburide; Metformin Hydrochloride.
Glucovance has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Glucovance are:
- US6303146
- US6303146*PED
Glucovance was authorised for market use on 31 July, 2000.
Glucovance is available in tablet;oral dosage forms.
Glucovance can be used as treatment of type 2 diabetes.
The generics of Glucovance are possible to be released after 14 January, 2020.
Drugs and Companies using GLYBURIDE; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 31 July, 2000
Treatment: Treatment of type 2 diabetes
Dosage: TABLET;ORAL
How can I launch a generic of GLUCOVANCE before it's drug patent expiration?
More Information on Dosage
GLUCOVANCE family patents
